Convatec’s Extracellular Matrix Wound Care Cleared

FDA has cleared a Convatec 510(k) for its InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The product is made with Convatec’s proprietary TriCleanse Placental Extracellular Matrix Process, “which thoroughly decellularizes the [extracellular matrix] ECM, disinfects the tissue and deactivates viruses while maintaining structural proteins that help with healing,” the company says.

InnovaMatrix PD is indicated for managing wounds, including full- and partial-thickness wounds, surgical wounds and traumatic wounds. The device can be used to treat traumatic lacerations, dehisced incisional wounds, pressure and venous ulcers, post-Mohs surgery wounds, partial thickness burns, post-surgical incisions and diabetic foot ulcers, the company says, adding that the device requires no preparation, no tissue tracking and no special storage.